Clinical trial · Observational
Basal Like Bladder Cancer : Signature and Therapeutic
Identification and Treatments of Basal Like Bladder Cancer (Study on Human Tumor Samples and Animal Models)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Muscle invasive (MIBC) and/or metastatic bladder cancer is associated with poor prognosis and no target therapies for this pathology are currently validated. By 40 gene expression signature realized on frozen samples, we have previously identified an aggressive sub-class of MIBC, called basal. This sub-class (20% of MIBC) showed strong EGFR dependence in vitro and in vivo (Rebouissou et al. Science Translational Medicine 2014). This observation suggests a possible response to EGFR targeted therapy in patients of this subgroup. Our aim is to establish a standard diagnostic tool to differentiate the basal subtype of bladder cancer and evaluate the effect of anti-EGFR therapy, by analyzing previous clinical trial (GETUG19) and preclinical models, which compare the classical chemotherapy to anti-EGFR associated chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Molecular Taxonomy | — | UNRESOLVED | — |
| Muscle Invasive Bladder Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biomarker study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- A
- description
- 120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.
- interventionNames
- Other: biomarker study
- label
- B
- description
- 510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.
- interventionNames
- Other: biomarker study
- label
- C
- description
- 188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.
- interventionNames
- Other: biomarker study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Muscle invasive bladder cancer Treatment by cystectomy Adjuvant chemotherapy for 3rd cohort Clinical trial GETUG 19 for 4th cohort Exclusion Criteria: FFPE material not available Follow-up data not available
References
Publications (0)
Data not yet available